Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2024 Oct 9

PMID 39384712

Authors

Virendra Singh

Arka De

Rishav Aggrawal

Akash Singh

Swati Charak

Naveen Bhagat

Affiliations

Soon will be listed here.

Abstract

Background: In cirrhosis, activation of renin-angiotensin-aldosterone system leads to sodium and water retention causing ascites. Dapagliflozin, a sodium glucose linked transporter-2 inhibitor, induces natriuresis in patients with heart failure. A similar natriuretic effect may improve ascites in patients with cirrhosis. In this pilot study, we evaluated the safety and efficacy of dapagliflozin in patients with cirrhosis and recurrent ascites.

Methods: Forty patients with recurrent ascites and cirrhosis were randomized to 1:1 in a double blinded fashion to receive either dapagliflozin (10 mg/day) with standard medical therapy (Group A) or placebo with standard medical therapy (Group B). The primary outcome was control of ascites at 6 months. Secondary outcomes were urine output, 24-h urinary sodium, Child Turcotte Pugh (CTP), model for end-stage liver disease (MELD) scores, survival at 6 months, incidence of acute kidney injury (AKI) and infections.

Results: The 2 groups were comparable at baseline. Control of ascites at 6 months was significantly better in group A than that in Group B (p = 0.04). Change in urinary sodium was significantly higher in Group A (p < 0.001]. However, there was no difference in change in urine output, CTP or MELD scores and survival (65% vs 72.2%, p = 0.75) between the groups at 6 months. Incidence of AKI (50% vs 15%, p = 0.04) and infections (55% vs 20%, p = 0.04) were significantly higher in Group A.

Conclusion: Significantly better control of ascites and higher natriuresis are observed with dapagliflozin. However, it does not improve disease severity scores or survival, and is associated with increased AKI and infections (NCT05014594).

References

Schrier R, Arroyo V, Bernardi M, Epstein M, Henriksen J, Rodes J . Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988; 8(5):1151-7. DOI: 10.1002/hep.1840080532. View

Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V . Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015; 63(5):1272-84. DOI: 10.1016/j.jhep.2015.07.004. View

Singh V, De A, Mehtani R, Angeli P, Maiwall R, Satapathy S . Asia-Pacific association for study of liver guidelines on management of ascites in liver disease. Hepatol Int. 2023; 17(4):792-826. DOI: 10.1007/s12072-023-10536-7. View

Aithal G, Palaniyappan N, China L, Harmala S, Macken L, Ryan J . Guidelines on the management of ascites in cirrhosis. Gut. 2020; 70(1):9-29. PMC: 7788190. DOI: 10.1136/gutjnl-2020-321790. View

Biggins S, Angeli P, Garcia-Tsao G, Gines P, Ling S, Nadim M . Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021; 74(2):1014-1048. DOI: 10.1002/hep.31884. View

Dhillon S . Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019; 79(10):1135-1146. PMC: 6879440. DOI: 10.1007/s40265-019-01148-3. View

Kosiborod M, Jhund P, Docherty K, Diez M, Petrie M, Verma S . Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation. 2019; 141(2):90-99. PMC: 6964869. DOI: 10.1161/CIRCULATIONAHA.119.044138. View

Miyamoto Y, Honda A, Yokose S, Nagata M, Miyamoto J . The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. J Clin Med. 2023; 12(6). PMC: 10056954. DOI: 10.3390/jcm12062253. View

Montalvo-Gordon I, Chi-Cervera L, Garcia-Tsao G . Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. Hepatology. 2020; 72(5):1880-1882. DOI: 10.1002/hep.31270. View

10.

Miyamoto Y, Honda A, Yokose S, Nagata M, Miyamoto J . Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor. Clin Kidney J. 2022; 15(4):831-833. PMC: 8967662. DOI: 10.1093/ckj/sfab266. View

11.

Kalambokis G, Tsiakas I, Filippas-Ntekuan S, Christaki M, Despotis G, Milionis H . Empagliflozin Eliminates Refractory Ascites and Hepatic Hydrothorax in a Patient With Primary Biliary Cirrhosis. Am J Gastroenterol. 2020; 116(3):618-619. DOI: 10.14309/ajg.0000000000000995. View

12.

Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K . Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021; 51(7):725-749. DOI: 10.1111/hepr.13678. View

13.

Singh V, Dhungana S, Singh B, Vijayverghia R, Nain C, Sharma N . Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol. 2011; 56(2):348-54. DOI: 10.1016/j.jhep.2011.04.027. View

14.

Saffo S, Taddei T . SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis (Hoboken). 2019; 11(6):141-144. PMC: 6385962. DOI: 10.1002/cld.714. View

15.

Li H, Tse Y, Chandramouli C, Hon N, Cheung C, Lam L . Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. J Clin Endocrinol Metab. 2022; 107(12):3442-3451. PMC: 9693836. DOI: 10.1210/clinem/dgac558. View

16.

Ekpanyapong S, Reddy K . Infections in Cirrhosis. Curr Treat Options Gastroenterol. 2019; 17(2):254-270. PMC: 7101776. DOI: 10.1007/s11938-019-00229-2. View

17.

Bajaj J, Kamath P, Reddy K . The Evolving Challenge of Infections in Cirrhosis. N Engl J Med. 2021; 384(24):2317-2330. DOI: 10.1056/NEJMra2021808. View

18.

Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J . Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology. 2018; 156(5):1368-1380.e10. DOI: 10.1053/j.gastro.2018.12.005. View

19.

Ohara K, Masuda T, Morinari M, Okada M, Miki A, Nakagawa S . The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease. Diabetol Metab Syndr. 2020; 12:37. PMC: 7195732. DOI: 10.1186/s13098-020-00545-z. View

20.

Hallow K, Helmlinger G, Greasley P, McMurray J, Boulton D . Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2017; 20(3):479-487. DOI: 10.1111/dom.13126. View